PT1931697E - Antagonistas de il-17a e il-17f e processos para a sua utilização - Google Patents

Antagonistas de il-17a e il-17f e processos para a sua utilização Download PDF

Info

Publication number
PT1931697E
PT1931697E PT06815733T PT06815733T PT1931697E PT 1931697 E PT1931697 E PT 1931697E PT 06815733 T PT06815733 T PT 06815733T PT 06815733 T PT06815733 T PT 06815733T PT 1931697 E PT1931697 E PT 1931697E
Authority
PT
Portugal
Prior art keywords
polypeptide
cells
quot
seq
disease
Prior art date
Application number
PT06815733T
Other languages
English (en)
Portuguese (pt)
Inventor
Mark W Rixon
Steven D Levin
Zeren Gao
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of PT1931697E publication Critical patent/PT1931697E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT06815733T 2005-09-28 2006-09-28 Antagonistas de il-17a e il-17f e processos para a sua utilização PT1931697E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72116205P 2005-09-28 2005-09-28
US75379405P 2005-12-22 2005-12-22
US77202206P 2006-02-10 2006-02-10
US78224706P 2006-03-14 2006-03-14

Publications (1)

Publication Number Publication Date
PT1931697E true PT1931697E (pt) 2010-12-06

Family

ID=37672342

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06815733T PT1931697E (pt) 2005-09-28 2006-09-28 Antagonistas de il-17a e il-17f e processos para a sua utilização

Country Status (16)

Country Link
US (1) US20070238658A1 (enExample)
EP (1) EP1931697B1 (enExample)
JP (1) JP2009510093A (enExample)
KR (1) KR20080056241A (enExample)
AT (1) ATE481424T1 (enExample)
AU (1) AU2006294511B2 (enExample)
BR (1) BRPI0616589A2 (enExample)
CA (1) CA2621623A1 (enExample)
CY (1) CY1110856T1 (enExample)
DE (1) DE602006016965D1 (enExample)
DK (1) DK1931697T3 (enExample)
EA (1) EA015351B1 (enExample)
IL (1) IL189726A0 (enExample)
PL (1) PL1931697T3 (enExample)
PT (1) PT1931697E (enExample)
WO (1) WO2007038703A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259638C1 (en) 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
BRPI0511952A (pt) 2004-06-10 2008-01-29 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PL2481756T3 (pl) 2005-10-31 2018-02-28 Oncomed Pharmaceuticals, Inc. Kompozycje i sposoby diagnozowania i leczenia nowotworu
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
WO2007071439A1 (en) * 2005-12-22 2007-06-28 Laboratoires Serono S.A. Soluble il-17rc variant and uses thereof
US7622116B2 (en) * 2006-02-10 2009-11-24 Zymogenetics, Inc. Method of treating inflammation using soluble IL-17RCX4
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
US7790676B2 (en) * 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008131315A2 (en) * 2007-04-20 2008-10-30 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
KR101805201B1 (ko) 2009-03-30 2017-12-05 악셀레론 파마 인코포레이티드 Bmp-alk3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
CN102869678A (zh) 2009-08-27 2013-01-09 科瓦根股份公司 Il-17结合化合物及其医药用途
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
AU2019333059A1 (en) * 2018-08-29 2021-03-18 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion protein dosing regimens
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
WO2025226984A1 (en) * 2024-04-24 2025-10-30 Mopac Biologics, Inc. Human il-17 binding polypeptides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2237039A1 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
CA2328496C (en) * 1998-05-15 2016-01-05 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
JP4737903B2 (ja) 1999-07-07 2011-08-03 ザイモジェネティクス, インコーポレイテッド ヒトサイトカイン受容体
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
WO2001090358A2 (en) * 2000-05-24 2001-11-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Il−17アンタゴニストを使用する慢性関節リューマチの治療法
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
JP2006508056A (ja) * 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
AU2004259638C1 (en) * 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
BRPI0511952A (pt) 2004-06-10 2008-01-29 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14

Also Published As

Publication number Publication date
EA200800956A1 (ru) 2008-12-30
PL1931697T3 (pl) 2011-03-31
BRPI0616589A2 (pt) 2011-06-28
CA2621623A1 (en) 2007-04-05
WO2007038703A2 (en) 2007-04-05
WO2007038703A3 (en) 2007-07-05
CY1110856T1 (el) 2015-06-10
ATE481424T1 (de) 2010-10-15
EA015351B1 (ru) 2011-06-30
DE602006016965D1 (de) 2010-10-28
US20070238658A1 (en) 2007-10-11
EP1931697A2 (en) 2008-06-18
AU2006294511A1 (en) 2007-04-05
AU2006294511B2 (en) 2011-11-17
IL189726A0 (en) 2008-08-07
JP2009510093A (ja) 2009-03-12
EP1931697B1 (en) 2010-09-15
HK1112927A1 (en) 2008-09-19
DK1931697T3 (da) 2010-11-08
KR20080056241A (ko) 2008-06-20

Similar Documents

Publication Publication Date Title
PT1931697E (pt) Antagonistas de il-17a e il-17f e processos para a sua utilização
ES2718474T3 (es) Receptores murinos de células T anti-NY-ESO-1
ES2872077T3 (es) Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
AU2016334051B2 (en) Anti-TREM2 antibodies and methods of use thereof
EP2315776B1 (en) T cell receptors and related materials and methods of use
CN102149730B (zh) Fgf-r4受体特异性拮抗剂
ES2742456T3 (es) Regímenes de tratamiento utilizando anticuerpos anti-NKG2A
ES2925307T3 (es) Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II
TWI527830B (zh) 介白素-17a/f(il-17a/f)異源多肽及治療用途
BR112021008169A2 (pt) Domínio de ligação
UA125382C2 (uk) Антитіла проти людського vista та їх застосування
BRPI0906550B1 (pt) Anticorpo anti-tigit, usos de um anticorpo anti-tigit e métodos in vitro para estimular a interação de cd226-pvr e/ou a interação de cd96-pvr, para aumentar ou estimular a proliferação de uma célula t ou a liberação de citocinas proinflamatórias por uma célula dendrítica, para aumentar ou estimular a resposta imune de célula t e para aumentar ou estimular a produção de citocinas proinflamatórias por uma célula dendrítica
JP5368400B2 (ja) Kim−1アンタゴニストおよび免疫系を調節するための使用
UA118950C2 (uk) Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
ES2284678T3 (es) Polipeptidos de claudinas.
JP2009515827A (ja) 治療薬
PT1812476E (pt) Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações
JP2008502312A (ja) ヒトIgGFcレセプターIIb(FcγRIIb)に結合する物質
WO2019129892A1 (en) T cell receptors for tumor specific proteasome splice variants and uses thereof
WO2010075417A1 (en) Survivin specific t cell receptor for treating cancer
ES2434721T3 (es) Un gen que codifica un homólogo de glicoproteína P humana multifármaco-resistente en el cromosoma 7p15-21 y usos del mismo
ES2391949T3 (es) Ácidos nucleicos, proteínas y anticuerpos BTL-II
ES2353117T3 (es) Antagonistas de il-17a e il-17f y métodos de uso de los mismos antagonistas de il-17a e il-17f y métodos de uso de los mismos.
US8614304B2 (en) Immunogenic peptides and methods of use for treating and preventing cancer
HK1260289B (en) Anti-trem2 antibodies and methods of use thereof